OICR’s Cancer Therapeutics Innovation Pipeline initiative funds M4K’s ALK2 program for DIPG as part of the inaugural set of projects

The Ontario Institute for Cancer Research (OICR) announced its Cancer Therapeutics Innovation Pipeline (CTIP) initiative and the first 10 projects selected for the inaugural round of funding. CTIP will support the local translation of Ontario discoveries into therapies by creating a new drug development pipeline and by working with the research teams to attract further investments for clinical development.

M4K Pharma’s project “An ALK2 inhibitor for diffuse intrinsic pontine glioma” was chosen as part of the first set of CTIP projects. Along with OICR and collaborators around the world, the drug discovery program aims at finding a medicine for a rare and deadly children’s cancer while testing whether using a fully ‘open science’ model will lead to lower costs associated with drug discovery and development, ultimately allowing for affordable pricing of the resulting medicine.